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R E P O R T
For more than 20 years, theAABB and theAmerican
Red Cross (ARC) have hosted the Immunohematology
Reference Laboratory (IRL) Conference in mid-spring.
Initially the conference was jointly hosted by the two
organizations; it has since been hosted alternately with
each organization choosing the host city and planning
the conference itinerary. The conference has been held
in various cities throughout the United States, including
Atlanta, Chicago, Las Vegas, New Orleans, Memphis,
Orlando, San Diego, and this year, Scottsdale,Arizona.
The conference begins on Friday afternoon with
proctor-led case studies discussing advanced immuno-
hematologic investigations, followed by a welcome
reception that promotes connecting and networking
with fellow technologists and physicians from around
the country and,typically,Canada. Saturday begins with
breakfast followed by speaker presentations on various
serologic, technical, clinical, administrative, quality, and
regulatory issues that affect today’s reference labora-
tories. These presentations extend until late afternoon
with scheduled breaks and a provided lunch. The
presentations continue on Sunday with the conference
ending at noon. Attendees are encouraged to bring
posters for viewing, and those who do so have the
opportunity to present the information to all.
Following are summaries of the presentations given
at the 2008 IRL conference that was hosted by theARC
fromApril 11 to 13 in Scottsdale,Arizona.
Leadership
Many individuals believe that to lead you must be at
the very top of an organization, but nothing could be
further from the truth. In successful organizations,
much of the leadership comes from below the top; in
fact, most comes from the middle of the organization.
Each of us can be a good leader, but we must work to
obtain the skills that good leaders possess. Leadership
is all about influence, getting people to follow you not
because of your position but because of who you are
and what you do. John Maxwell, a renowned author on
leadership principles,states“The true measure of leader-
ship is influence,nothing more,nothing less.” Influence
is defined as a power affecting a person,thing,or course
of events, especially one that operates without any
direct or apparent effort. Influence is not something
that is tangible,but the ability to influence is something
you have to earn and you can learn how to do it.
One can have influence by position, but the leader-
ship that results from this is very limited. People follow
you because they have to follow you, not necessarily
because they want to follow you. Leadership by posi-
tion doesn’t get one very far; it is limited by job
description, and although you do have influence, that
influence is limited. The ideal state is to be able to lead
individuals because they want you to lead them; they
allow you to influence them. They do this because they
respect you or admire you and know you care about
them as people. They see you as a person who gets
things done;they like what you are doing. They want to
be on your team!
To lead, one must prepare. A favorite quote comes
from JohnWooden. “When opportunity comes, it is too
late to prepare.” How true this is! We must be ready
to lead whenever and wherever the opportunity
presents itself. So how do we do that? First of all, as
John Maxwell discusses in his book The 360° Leader,
we must learn to manage ourselves. Sometimes this is
one of the most challenging aspects of being a leader. A
good leader knows when to show emotions and when
to hold them back. At times holding back one’s feelings
can be best for others; at other times a little show of
emotion from you is just what is needed by your team.
Knowing when and where to let your emotions out is
important. For example, you may be angry during a
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meeting because you are not getting the cooperation
you need from some of those at the table. Letting out
that anger inappropriately (i.e., pounding your fist on
the table or throwing something) will only make things
worse and lessen you in the eyes of those you lead.
Handling the situation in a calm, rational, and
professional manner will elevate you with others. They
want to be like you;you have more influence over them.
Leaders must also prioritize. All of us have many
things on our plate, and if we try to do everything, we
become ineffective, especially as leaders. Things slip
through the cracks and we constantly play catch up.
Learning to say“no”is difficult to do,but the good leader
is able to do this to benefit the organization as a whole.
A good leader delegates and allows others to do the
work, providing guidance as needed without micro-
managing.
Another area of leadership that requires self-
management is thinking. It is true that if you think bad
thoughts,bad things can happen. If you think someone
is less than a “10,” you may not give them a chance to
show you they are a“10.” If you think you can’t succeed,
you won’t. As a leader, you must also manage what you
say. Thinking before you speak is always a good practice,
and making sure that what you say has value is another.
Have you ever been in a meeting with someone who
always has to say something even when they have
nothing valuable to say? It is frustrating for everyone. If
people are going to spend their time listening to you,
what you say has to have value; otherwise, you are
wasting their time. Remember sometimes saying
nothing at all is best, especially if you have nothing
valuable to say.
Lastly, and I believe most importantly, a good leader
manages his or her personal life. Making time for family
and friends is critical,and doing things to get away from
the everyday drudgery of work is as well. Good leaders
have hobbies and outside interests; for example, they
watch or participate in sports, they read,and they travel
(not work travel, of course). Although it isn’t always
possible, good leaders also take care of physical needs
such as eating well,getting plenty of rest,and exercising.
Failing to take care of those physical needs can make
one an ineffective leader very quickly.
So what are the characteristics of an effective
leader? Leaders are secure and do not feel threatened by
others. They have vision and see the big picture; their
scope is outside of what is good for them and them
alone. They unselfishly look at what is good for those
whom they lead: the department, the organization, or
beyond. Real leaders are not chameleons; they do not
flip-flop on decisions,saying one thing to one person or
group because that is what they want to hear and
something different to another person or group because
that is what they want to hear. They make decisions and
use a good decision-making process. They know that
failing to make a decision is a decision and often a bad
one.
Leaders delight when those who follow them
succeed. They are not jealous that someone else is getting
some limelight; they are happy to share the kudos.
Leaders see everyone as a“10”and allow them a chance
to be that “10” by placing them in their strength zones.
Leaders truly care about the individuals they lead.They
see them as people with lives. Investing time in getting
to know those you lead not only helps you to understand
them better but it also builds trust. This trust allows you
to gain influence with them,and they are more willing to
follow you. A good leader invests power in others,setting
reasonable goals and supporting individuals when
needed but not totally controlling them. Leaders praise
accomplishments publicly and constructively criticize
privately behind closed doors. Good leaders are loyal to
those who follow them. Additional good leadership
practices include the following:
• Being prepared—Leaders do their homework.
They understand what the desired results are,how
they are trying to achieve those results, and what
the issues in achieving those results are.
• Communicating well—Leaders communicate
horizontally and vertically. They communicate
clearly and directly. They listen well and they
inform others appropriately as needed.
• Setting good goals—Leaders set goals that are
realistic but they push the envelope, challenging
within limits those who follow them. They don’t
ask others to do what they would not do.
• Modeling the behavior you want to see in others
(i.e., walking the talk)—Leaders are role models
and exhibit those characteristics they want to see
in those who follow them. They never just give
“lip service.”
• Using data and facts to make decisions—Whereas
sometimes good leaders go with intuition,when-
ever possible, they make decisions based on good
data and facts.
• Managing conflict instead of avoiding it—Leaders
are not afraid of conflict. Although they don’t seek
to create it, when it occurs they facilitate its
resolution.
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As you can see, leadership is much more than
management. Management is about projects; leadership
is about people. Management is about procedures and
rules; leadership is about vision and relationships. The
leader looks to the future; the manager maintains and
implements what is the current state.
Not everyone is born a leader and not everyone can
be at the top of the organization,but everyone can lead.
Working on those areas discussed above will prepare
you to lead whenever and wherever the opportunity
arises.
Eva D.Quinley, MS, MT(ASCP)SBB, CQA(ASQ), Senior
Vice President, Quality and Regulatory Affairs,
American Red Cross,Washington, DC.
Decision-Making When All RBCs Tested Are
Incompatible
When all, or most, RBCs react during compatibility
testing, there are several causes to be considered, and
questions to be answered, depending on whether the
RBCs in question are from donor units, reagent RBCs,or
both:
1. Autoantibody or alloantibody, or both?
2. Alloantibody to high-prevalence antigen?
3. Mixture of several alloantibodies?
4. Not an antibody to RBC antigens?
5. Is antibody clinically significant?
Items 1, 2, and 3 are the “bread and butter” of IRLs,
so will not be discussed in great detail. Questions 4 and
5 are sometimes more difficult for even a sophisticated
IRL to answer.
When all tested reagent RBCs react, sometimes it is
attributable to antibodies that are reacting with antigens
that are not blood group antigens. These antigens may
be chemicals (e.g., antibiotics, sugars, EDTA, citrate,
hydrocortisone, inosine) in commercial reagents such as
RBC suspending media, antisera (e.g., dyes), or
potentiators (Paraben,azide, thimerosal). This becomes
obvious sometimes when reagents from other com-
panies and donor RBCs do not react. Other targets for
non–blood group antigens may be the senescent cell
antigen present on older RBCs. An unusual pheno-
menon has been described in which serum reacts with
all RBCs but plasma does not, and the DAT is positive
on RBCs from a clot but not an EDTA sample. This
condition is associated with ulcerative colitis. It has
been suggested that it is caused by antibody to serine
proteases (e.g., produced during clotting).
Several approaches have been used to predict the
clinical significance of an antibody (e.g., thermal
amplitude, specificity, functional cellular assays, and
51Cr RBC survival). A major problem is defining what
clinical significance means. Do we want tests to predict
whether transfused RBCs will survive normally, or are
we satisfied if the antibody does not cause morbidity in
the patient? It may be that the first is better for patients
with hematologic disease, but the second is acceptable
for most other patients.
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Compliance to Quality: A Journey
We are a focused industry, focused on compliance,
and maybe sometimes so focused on compliance that
we let quality slide. Now, there is a controversial
statement. In a world in which the Food and Drug
Administration rules and we have the AABB Standards
to abide by, how can such a statement be made? Many
of us look at compliance and quality as totally inter-
changeable, but in reality they are not. To explore how
we might want to change our focus from one bent on
compliance to one bent on quality, let’s talk about a
journey—a journey from compliance to quality. By the
way, for those of you who are gasping for air about now,
I am not saying away from compliance but rather from
compliance focused to quality focused. This doesn’t
mean you are going to stop being compliant—quite the
opposite. In a true quality organization,compliance is a
byproduct in all you do.
First of all, let’s talk about the differences between
compliance and quality. Compliance by definition
means bending to the will of others; it is the act of
submitting. A total focus on compliance stifles creativity,
is reactive,and implies something is done to you. It can,
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and often does, create adverse relationships with those
who regulate us. Quality, on the other hand, leads to
compliance, generates new ideas, is proactive, and
promotes good relationships with regulators. Quality is
more than just compliance. So what is quality?
Quality is a matter of perception—McDonald’s
versus Chez Jardin. Which restaurant represents quality
depends on the requirements. Do you want a fast-food
meal that is consistently the same or a gourmet meal in
a quiet, candlelit dining room?
A good definition for quality is doing the right
things right the first time. If we know what the
requirements are, we do what we should do; we are
compliant. If we do things right the first time, we are
not only effective but we are also efficient. Quality is
the result of effectiveness and efficiency. You do what
you say you are going to do and you do it right with the
least expenditure of resources. A quality organization is
by definition also a compliant organization because you
are doing the right things right. You also please your
customers because you know what their requirements
are and you work to meet those requirements each time
you do your work.
So, how do we achieve a quality focus? First of all
there are some important questions to ask. Does what
you are doing make sense? Is it the right thing to do? Is
it the right thing to do now? Is there an easier way to
do it (simpler is better)? Does the fear of making a
mistake paralyze you? Does change overwhelm you?
What are your customers’ requirements? Knowing the
answers to these questions and dealing with the difficult
ones before you begin the journey toward a quality
focus is critical to your success.
There are also some cautions you should remember
along the way:
(1) Don’t head down the wrong path by
implementing complex systems that hinder
you instead of helping you.
(2) Don’t yield to the temptation to tackle
everything at once.
(3) Know your capabilities.
(4) Be accountable.
Accountability, according to The OZ Principle, a
book by Roger Connors,Tom Smith,and Craig Hickman,
is the process of seeing,owning,solving,and doing. It is
a perspective that embraces both current and future
efforts rather than reactive and historical expectations.
Considering accountability, you will find some
dangerous detours in your journey to quality. Let’s take
a brief look at these.
Number 1—Ignoring problems or denying that you
have problems
People pretend not to know that there is a problem,
remain unaware that the problem affects them, or
choose to altogether deny the problem. This just doesn’t
work. You can’t fix problems unless you pay attention
to them. This is sort of like sticking your head in the
sand. You eventually are going to have to breathe, and
the problems won’t have gone away.
Number 2—It is not MY job!
In this case, there is an awareness that something
needs to be done to get the results, but there is also a
lack of responsibility or desire to involve oneself. As-
suming someone else will always pick up the ball is a
mistake; things fall through the cracks or, even worse,
nothing is done.
Number 3—Pointing fingers
People deny their own responsibility for poor
results and seek to shift the blame to others. This is a
total lack of accountability; someone else is always
responsible for the state of things. This is ignoring your
role in the situation, and usually you do have some role
in why things are as they are.
Number 4—Excuses
Making up excuses doesn’t get things fixed and may
even lead to solving the wrong problem.
Number 5—Confusion—Tell me what to do
People cite confusion as an excuse to avoid
accountability. If they don’t understand the problem or
the situation, surely they can’t be expected to do
anything about it. Or if you tell me what to do, then I
can’t be held accountable for what happens.
Number 6—Cover your tail
This happens when people seek “protection” by
developing“stories”as to why they couldn’t possibly be
blamed for something that might go wrong. Individuals
can be quite creative in making up these stories; again,
they hide the truth and avoid true accountability.
Number 7—Wait and see
In this dangerous detour,people choose to wait and
see whether things will get better. Typically, things only
get worse. Solutions get swallowed up in a swamp of
inaction. This type of behavior may be motivated by fear
of failure, risk aversion, or an unrealistic desire for a
better solution.
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The road to quality is not an easy road; avoiding
those detours can be hard. However, the road to quality
is a rewarding one. A key factor is to celebrate successes
(especially small ones), catch people doing the right
things right, create heroes, and recognize and reward
performance. Achieving quality is going beyond
compliance, and it allows you to meet your goals and
results in a strong organization. In a true quality org-
anization, the compliance is there. Lastly, remember,
quality is a journey and one which is truly worth
making.
Eva D.Quinley, MS, MT(ASCP)SBB, CQA(ASQ), Senior
Vice President, Quality and Regulatory Affairs,
American Red Cross,Washington, DC.
You Have Options . . . Immucor, Inc.
As the need for accurate, timely, and cost-effective
immunohematology diagnostic testing increases dramat-
ically across the world, Immucor stands as the largest
and best equipped corporation in North America to
provide the solutions needed to meet the needs of the
industry. Based in Norcross,Georgia, Immucor believes
in exceeding the needs of the customer. This starts by
understanding the requirements of the industry through
“voice of the customer”research. In 2007,this extensive
market research identified five key market needs in our
industry. Based on these findings,we concluded that the
blood bank customer most desires the following:
1. Full and reliable blood bank automation
2. A broad testing menu
3. A continuous access platform
4. A fast turnaround time
5. Automation and test methods that are easy to use
Immucor is meeting these needs through the
delivery of superior products in our Scalable Solutions
automated product line, which includes the Capture
workstation, the Galileo, and the Galileo Echo.
Immucor’s manual Capture workstation features the
P2 dual-plate incubator, the CSW100 plate washer, and
the Immuspin centrifuge. Perfect for smaller laborato-
ries or as a backup to large, fully automated laboratories,
the Capture workstation provides standardized test
results every time. For more than 20 years, thousands of
laboratories across the globe have trusted Capture solid-
phase technology, with more than 30 million Capture
tests performed annually.
Galileo, Immucor’s flagship instrument, has revo-
lutionized transfusion diagnostics with its speed and
flexibility. Galileo was the first automated system
designed to meet the workflow of a transfusion diag-
nostics laboratory,not change it. With a broad test menu,
high throughput coupled with a quick turnaround time,
reflex testing,and an intuitive user interface,Galileo has
become the gold standard in automated platforms.
With high demand for the features of the Galileo in
a smaller package, Immucor developed the Galileo
Echo—a revolutionary instrument that delivers the
benefits of Galileo for smaller laboratories. Echo was
designed to perform a record number of assays with the
industry’s smallest footprint.
However,meeting the customer’s needs requires not
only superior products, but also a superior approach.
Anchored by our Blood Bank System Specialists, the
Immucor team is dedicated to providing a solution for
these key industry needs, or “drivers.” This includes
coupling blood bank reagent options and instrument
platforms with an implementation process called“Lean.”
Lean is a continuous improvement philosophy that
is used to eliminate waste and variation. It is widely
used today in the health-care diagnostics industry to
improve quality and response times while maintaining
or decreasing expenditures. Immucor has invested in
our people to make them Lean-certified under the Lean
HealthCare Institute banner, with the express purpose
to pass on their skills to Immucor customers by install-
ing and integrating all products into the customer’s
specific environment appropriately.
This results in a customized solution for each
laboratory location. This customized solution may in-
clude layout and process enhancements through the
Lean methodology. It might also include technology
enhancements through Immucor’s networked auto-
mation. Immucor, through a partnership with Data
Innovations, uses a variety of networking methods,
including remote access and wide area networked
innovations, to meet the data needs of the customer,
ensuring that they have the right information at the
right time.
Through dedication and the drive to exceed
expectations, Immucor is committed to meet and
exceed the needs of the customer.
Theresa Heflin,VP Marketing, Immucor, Inc., Norcross,
GA.
The Journey to Licensure
The Diagnostic Manufacturing Division (DMD) of
the American Red Cross (ARC) fully manufactures
licensed and 510(k) cleared immunohematology
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reagents in accordance with current Good Manufac-
turing Practices and 21CFR, parts 600 and 800. These
products are distributed toARC NationalTesting Labora-
tories and Immunohematology Reference Laboratories
and various non–ARC organizations. As a constituent of
the ARC, the mission of the DMD is to support its
customers with the highest quality, cost-effective
reagents and ancillary products. To that end,DMD uses
a quality system that includes change management,
document control, training, supplier evaluation, in-
coming goods specifications and inspection, in-process
controls, contamination controls, environmental moni-
toring, labeling and packaging controls, final product
testing, design control, equipment and process valida-
tion, equipment maintenance and calibration,deviation
management, corrective and preventive action plans,
nonconforming product control, product complaint
management, internal audits, and management review.
Established in 1976, DMD has manufactured from
four locations. The 1998 move to the current location
required DMD to once again obtain licensure to
manufacture licensed blood grouping reagents through
the Biologics License Application (BLA) process.
A 2001 BLA supplement was withdrawn primarily
because of an inability to meet FDA sterility require-
ments. A different approach using a microbiologically
controlled process was developed,and a manufacturing
process was designed to ensure the microbial level will
not adversely impact product performance. The
philosophy is based on two distinct elements and the
results of supportive studies:
Environmental Monitoring
• Air
• Surfaces
• Water
• Personnel (gowning)
Bioburden Reduction
• Product filtration
• Process equipment cleaning
• Heat treatment of product components
(containers/closures)
• Product preservative (sodium azide, 0.1%)
Supportive Validation Studies
• Bioburden monitoring of in-process material
• Airborne baseline levels
• Sodium azide effectiveness
• Equipment cleaning
• Closure integrity of filtration vessel
• Closure integrity of final product containers
• Media fill—tryptic soy broth substituted for
product
Final product contamination testing demonstrates
the product meets the DMD microbiologically con-
trolled standard.
A BLA supplement was submitted in 2005 that
contained the following required elements:
• Cover letter
• FDA forms (2)
• Introduction—executive summary
• Proposed labeling (all labels and package inserts)
and packaging
• Chemistry,manufacturing, and controls (CMC)
– Extensive description of in vitro substance
(active ingredient) and in vitro product
- Composition—ingredients and formulas
- Characterization—test method descriptions
and applications
- Method of manufacture—raw materials and
acceptance criteria, flow charts
- Process controls—in-process controls,process
validation, bioburden assessment
- Reference standards
- Specifications and analytical methods
- Container closure system—description and
validation
- Stability data
– Environmental monitoring data
- Air
- Water
- Surfaces
- People
- In-process bioburden
– Batch records—6 conformance lots
– Validation (process and equipment) summaries
• Establishment description
– Physical description, floor plans
– Cross-contamination controls
– Environmental monitoring
– HVAC system and validation
– Water system and validation
The DMD submission totaled 1315 pages that
thoroughly explained the microbiologic control “story,”
supplied data to support the“story,”and provided details
about the product composition,manufacturing process,
test methods, and conformance lot production.
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DMD was granted licensure in 2006 for anti-Fya and
anti-K and in 2007 for anti-S and anti-k. Another BLA
supplement will occur in 2008 for anti-M,anti-s,anti-Kpa
and anti-Kpb.
Elizabeth Cummings, Diagnostic Manufacturing
Division, American Red Cross, Rockland, MD.
Serologic Investigation of Autoimmune
Hemolytic Anemia
Autoimmune hemolytic anemia can be classified as
those anemias associated with (1) antibodies reacting
optimally at 37°C (“warm type”AIHA [WAIHA] = 80%),
and (2) antibodies reacting optimally below 10°C (cold
agglutinin syndrome [CAS] = 18%,and paroxysmal cold
hemoglobinuria [PCH] = 2%).
• WAIHA: Usually IgG autoantibody,but can be IgM
or IgA. DAT: IgG + C3 (67%), IgG without C3
(20%),C3 without IgG (13%). In vitro lysis of RBCs
is uncommon (0.8% untreated, 13% enzyme-
treated); 35 percent will have cold agglutinins
active at room temperature. Usually extravascular
lysis. Most common specificity is Rh-related, but
almost all high-frequency antigens have been
involved.
• CAS: IgM high titer/thermal amplitude (≥30°C);
cold agglutinin. Cold monophasic lysin usually
present.DAT:C3dg only.Extravascular in vivo lysis.
Usually anti-I.
• PCH: Rarest type of AIHA (<2%). More common
in children (infection associated) than adults.
Usually intravascular lysis. DAT: C3dg only.
Biphasic (sensitized in cold, hemolysis when
moved to 37°C) cold lysin detected by Donath
Landsteiner (DL) test. DL antibody has anti-P
specificity.
• DAT-NegativeAIHA: Approximately 10 percent of
WAIHA. Can be caused by RBC-bound IgG below
DAT sensitivity threshold, low-affinity autoanti-
body, IgA or IgM warm antibody. Helpful tests are
direct Polybrene test, DAT using anti-IgA/IgM,
using ice-cold saline or LISS washes for DAT, or
flow cytometric DAT.
• WAIHA Associated With IgM Autoantibodies:
Often, severe AIHA, sometimes intravascular lysis.
Spontaneous agglutination of patients’RBCs often
(78%) occurs; C3dg on RBCs (90%); IgM on RBCs
(62%) but not often (30%) detected by DAT.
Sometimes (25%) IgG also present. Serum usually
(80%) contains 37°C-reactive agglutinins.
Childhood AIHA:
• Acute transient: Acute transient AIHA 10× more
common in children than adults; 82 percent in
first 4 years; 68 percent associated with infection;
45 percent have hemoglobinuria (71% of sudden
onset); 59 percent have only C3dg on RBCs; 12
percent have positive DL test. Respond well to
steroids. Low fatality rate.
• Chronic WAIHA: Often (58%) associated with
systemic disorders;only 44 percent in first 4 years;
85 percent have IgG,with or without C3,on RBCs.
Variable response to steroids;12 percent mortality.
Reference
1. Petz LD, Garratty G. Immune hemolytic anemias.
2nd ed. Philadelphia:Churchill Livingstone, 2004.
George Garratty, PhD, FRCPath, Scientific Director,
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Controversies in Testing
Although the practice of blood banking and
transfusion medicine may,at times,seem to be driven by
regulators, there still remain many opportunities for
variation in applying the regulations to actual daily
operations. Adaptation of new technologies also affords
the possibility of different applications. Controversies
over what acceptable or best practices may look like
arise. Several of these were more closely examined.
Criteria for Exclusion of Alloantibodies
A critical control point in identification of RBC
antibodies is antibody exclusion. This ensures that there
are no other unexpected antibodies in the sample that
may have been masked by the reactivity of the known
antibodies. The process of antibody exclusion requires
decisions on what alloantibodies will routinely be
investigated and excluded and what criteria will be used
for exclusion. The following options exist for exclusion:
(1) using RBCs that carry a single dose or presumed
double dose of the antigen in question;(2) using only in-
date reagent RBCs or allowing the use of expired reagent
RBCs; or (3) excluding an antibody specificity on the
basis of one nonreactive antigen-positive RBC sample or
requiring two or more antigen-positive RBC samples to
be nonreactive. Decisions on these options constitute
the policy for antibody exclusion in a given facility.
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The biggest controversy in antigen exclusion
centers on the number of antigen-positive RBC samples
that must be nonreactive to exclude the antibody. Use
of one RBC sample for exclusion allows antibodies to
be excluded more easily with minimal sample. It also
can affect the selection of units for transfusion because
when an antibody is excluded, donor units negative for
that antigen are not required for transfusion. However,
reliance on a single RBC sample for exclusion does not
allow for any error in testing or unknown variation in
antigen expression. A policy that requires nonreactivity
with two or more antigen-positive RBC samples to
exclude an antibody compensates for these unexpected
events. However, this practice can require a greater
inventory of test RBCs and will likely use more patient
sample.
An e-mail survey ofAABB-accredited Immunohema-
tology Reference Laboratories (IRL) and American Red
Cross (ARC) IRLs was conducted in mid-2007 to assess
policies related to the number of exclusion RBCs
required. Of 63 laboratories responding, 42 facilities
(67%) used only one nonreactive RBC sample to exclude
an alloantibody. Comments from the responding labora-
tories were “require one example of double-dose RBCs
but more than one example if the RBCs express a single
dose of the antigen,” or “one double dose required
except for anti-K and anti-C or anti-E in presence of anti-
D.” Several laboratories required more than one
antigen-negative RBC sample for clinically significant
alloantibodies but only one example for antibodies not
generally clinically significant.
Considering the pros and cons of various exclusion
issues, one protocol that might be used would be as
follows:
• For Rh, Fy, Jk, Ss antibodies
– At least two antigen-positive RBC samples are
nonreactive
– At least one example of the RBCs has a double
dose expression of the antigen except when
excluding anti-C or anti-E in the presence of anti-
D or excluding anti-K
– If the exclusion RBC sample does not have a
double dose of the antigen,the test method used
must be PEG, gel, solid-phase, or enzyme (if
appropriate)
– If expired RBCs must be used, they must be
double dose
• For MN,Lewis, P1 antibodies
– One RBC sample for exclusion
– Double dose, if appropriate
Reactivity inVarious Test Methods
Many test methods are available for use in blood
bank testing today: tube techniques (LISS or PEG) and
non–tube techniques (automated and manual gel or
automated and manual solid phase). In general, com-
parative studies have shown that non-tube methods are
more sensitive than tube methods in detecting clinically
significant alloantibodies. However, non-tube methods
can also be less specific than tube methods. That is,
when reactivity is detected in a tube method, it is more
likely to be an alloantibody.
Most participants in the ARC IRL Conference
represented laboratories receiving the majority of their
samples from other blood bank laboratories. These
referral laboratories primarily used tube techniques for
routine testing; some could also perform gel testing. A
very few could perform solid-phase tests. The hospital
laboratories represented reported using both tube and
gel methods. Virtually all hospital laboratories used the
same method for initial antibody identification as
antibody detection, although a second method would
be used when the primary method does not indicate
clear specificity.
Various scenarios were posed giving options for
testing when nonspecific reactivity or panagglutination
was observed in initial non-tube identification tests.
Conference participants often indicated that tube test
methods (LISS or PEG) would be used when an appar-
ent autoantibody was detected in non-tube tests.
Sporadic reactivity in non-tube tests would most often
be approached by performing antibody exclusions in
the non-tube test followed by selection of donor units
based on a compatible crossmatch. When initial non-
tube tests that react with many cells on a panel are
encountered,some of the laboratories will revert to non-
tube methods to look for specificity.
When designing antibody identification protocols
combining tube and non-tube tests, it must be
remembered that no single protocol is correct. The
selected protocol must balance appropriate inves-
tigation of reactivity with timely provision of test results
and blood products. Change in the reactivity in a
patient’s sample after transfusion may be an indicator
for more rigorous testing by non-tube methods.
Provision of Genotype-Matched Units forWAA
Patients
The availability of large scale, batch genotyping for
patient and donor samples has opened new possibilities
for selection of units for transfusion. Patients with warm
autoantibody in the serum can require complex
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adsorption studies to exclude alloantibodies. It has been
suggested that genotyping for common RBC antigens
could eliminate the need for evaluation of the sample
using adsorptions if genotypically matched donor units
were selected for transfusion.
Several concerns of both serologic and logistic
nature have been raised for this type of protocol.
Although readily available in the commercial setting,
genotype testing must be performed in laboratories
having personnel with the appropriate skill set for
accurate performance, interpretation,and application of
the test. A patient’s genotype may not represent the RBC
phenotype. Because of unrecognized mutations, a
patient may appear to be antigen positive but still be
capable of making the alloantibody. Logistically, the
genotyping assays are not licensed for labeling of donor
units with phenotype information. RBC phenotypes
must be confirmed serologically. The impact on blood
suppliers must also be considered. Large-scale donor
phenotyping is not routinely available in donor centers.
If a hospital transfusion service implements a protocol
of genotype matching, the donor center must identify
the matched units through labor intensive, manually
performed serologic antigen typing. The blood centers
must be prepared to allocate financial and personnel
resources for this approach.
The protocol may first be used in patient popu-
lations such as patients with sickle cell anemia in whom
genetic variation in RBC antigens is more commonly
encountered and the benefits of phenotypically matched
units have been demonstrated. Routine use in warm
autoantibody patient populations for the pur-pose of
streamlining pretransfusion testing may not be justified
until genotyping in donor centers is readily available.
Controversies in testing patterns and protocols will
routinely present themselves as new technologies and
techniques are developed. Critical evaluation of the
information and analysis of the impact on both patient
care and provision of blood products for transfusion will
result in wise choices that meet the needs of patients
and transfusion medicine providers.
Janis R.Hamilton, MS, MT(ASCP), Manager, Immuno-
hematology Reference Laboratory, American Red
Cross, Southeastern Michigan Region, Detroit, MI.
Blood Doping in Athletes—Detection by
Flow Cytometry
In sports, the term “doping” refers to the use of
performance-enhancing substances or methods. Anti-
doping rules have been adopted not only for the health
and safety of the athlete but also to “protect the ethics
underlying sports.”1 Blood doping refers to the use of
methods to increase circulating hemoglobin levels. The
resulting increase in the oxygen concentration of
arterial blood can be an advantage for athletes both in
competition and in training. Three methods athletes can
use for this are (1) autologous or allogeneic blood
transfusion, (2) pharmacologic products (e.g., recom-
binant human erythropoietin, rHuEPO) that stimulate
overproduction of RBCs in the bone marrow, and (3)
blood substitutes. Transfusion has been rumored to be
used by athletes since the 1960s. There are anecdotal
reports of its decline when rHuEPO was introduced in
the late 1980s,but purportedly implementation of a test
to detect rHuEPO in 2000 has driven athletes back to
transfusion. Flow cytometry was first used for the de-
tection of allogeneic transfusion in athletes at the 2004
Summer Olympics in Athens (there are currently no
methods to detect autologous transfusion).
Flow cytometry is ideally suited for the detection
and quantitation of mixed cell populations because each
cell is analyzed individually. Subpopulations of RBCs can
be detected based on their antigenic differences (via
fluorochrome-labeled antibodies), and quantitative
results can be obtained. Flow cytometry has been
successfully used since the 1980s for the detection and
quantitation of minor RBC populations in the following
situations: fetal-maternal hemorrhage,survival studies in
transfused patients, individuals with blood group
mosaicism, and hematopoietic chimerism in twins and
bone marrow/stem cell transplant patients. Recent
publications have addressed the use of flow cytometry
in the setting of blood doping.2–6
Technical Considerations
Flow cytometry is widely used forWBC analyses and
less commonly for RBC analyses. Thus, most flow
cytometry operators are not familiar with issues
associated with testing RBCs (e.g., problems associated
with agglutination);some methods that pertain toWBCs
(e.g., incubations at 4°C to prevent capping) do not
apply to RBCs. Agglutination is the biggest problem
facing those analyzing RBCs by flow cytometry. The best
flow cytometric test would involve incubation of test
RBCs with a nonagglutinating, strongly fluorescent IgG
blood group antibody. Unfortunately, these types of
antibodies are not readily available. The usual testing
protocol involves incubating test RBCs with a
commercial blood group antibody (e.g., anti-c, -K, -Fya,
etc.) and then a fluorochrome-labeled secondary
I M M U N O H E M A T O L O G Y, VO L U M E 2 4 , N U M B E R 2 , 2 0 0 8 71
2008 IRL Conference
antibody, e.g., FITC anti-IgG. Agglutination can occur
due to the primary or the secondary antibody and can
affect the results (the flow cytometer will count both a
single RBC and an agglutinated group of RBCs as one
event each). Agglutination can be avoided by using
nonagglutinating primary antibodies (if available) and
Fab fragments of fluorochrome-labeled secondary anti-
bodies. In some cases, chemical fixation of RBCs may
be needed to minimize agglutination. Primary and
secondary antisera used for this testing will need to be
standardized for use with RBCs by flow cytometry.
The RBC antigens that will be most helpful in
detection of transfused RBCs in athletes are those of
moderate frequency (A,B,D,C, c, E,M,N, S, s,K, Fya, Fyb,
Jka, Jkb). To be able to clearly distinguish antigen-positive
RBCs from antigen-negative RBCs (Fig.1), it is important
to use strong antibodies. Other factors that affect the
ability to discriminate antigen-positive from antigen-
negative RBCs include background fluorescence, the
number of antigen sites, and the method used to
sensitize or label the RBCs. The sensitivity for detection
of an antigen-positive minor RBC population is less than
1 percent, but detection of an antigen-negative minor
RBC population is more difficult (because of the
presence of nonfluorescent background events).
A false-positive result would involve the detection
of a second population of RBCs in an untransfused
athlete. This could be attributable to poor laboratory
techniques (wrong sample tested or contaminated
sample) or the presence ofWBCs in the sample. To have
confidence in the results,mixed populations for at least
two blood group antigens should be detected and the
percentages of the minor populations should be similar.
Antidoping test laboratories require repeat testing on a
stored aliquot if the initial results are positive.
Subsequent blood samples should be obtained from an
athlete to demonstrate a decrease in the minor
population over time. The athlete may claim that the
second population is the result of chimerism rather than
transfusion, but chimerism is unusual and could be
detected by molecular testing.
A false-negative result would involve not detecting a
second population of RBCs in a transfused athlete. It
would be unlikely that there would be no antigen
mismatches between the donor and recipient (unless
they were identical twins), but a difference in antigens
may not be detected if too few antibodies (or the wrong
antibodies) are tested. Poor techniques (insufficient
washing after incubation with antisera, presence of
agglutination, or suboptimal instrument set-up),
insufficient labeling of antigen-positive RBCs, or poor
quality of the blood sample could all lead to false
negative results.
In conclusion, flow cytometry is a good method to
detect allogeneic transfusion. It is important that the
testing laboratory be familiar with testing RBCs by
routine serology as well as by flow cytometry.
Patricia A. Arndt, MSMT, MT(ASCP)SBB, Senior
Research Associate, American Red Cross, Southern
California Region, Pomona, CA.
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Fig. 1. Mixed RBC populations.Fluorescence histograms showing results
of 5 percent s+ in s− RBCs (left histogram) and 5 percent s− in s+
RBCs (right histogram) after incubation with polyclonal anti-s and
then a fluorochrome-labeled Fab anti-human IgG. Markers are set
electronically around the two populations (M1 = antigen-negative
events, M2 = antigen-positive events) and quantitative results are
obtained.
